To investigate the effect of FK228 on the in vitro expression of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) by rheumatoid arthritis synovial fi broblasts (RASFs), and on the in vivo expression of VEGF and angiogenesis in the synovial tissue of mice with collagen-antibody-induced arthritis (CAIA). Methods: RASFs were stimulated with IL-1β and TNFα and then incubated under hypoxia (1 % O 2 ) with various concentrations of FK228. The effects of FK228 on the expression of HIF-1α and VEGF mRNA were examined by quantitative real-time PCR. Changes in HIF-1α protein expression and the secretion of VEGF protein into the culture medium were examined by Western blot analysis and ELISA, respectively. Immunohistochemical analysis was carried out to investigate the expression and distribution of VEGF in synovial tissues of CAIA mice. Results: The cytokine-stimulated expression of HIF-1α and VEGF mRNA was inhibited by FK228 in a dose-dependent manner. FK228 also reduced the expression of HIF-1α and VEGF protein. Intravenous administration of FK228 (2.5 mg/kg) suppressed VEGF expression, and also blocked angiogenesis in the synovial tissue of CAIA. Conclusion: FK228 may exhibit a therapeutic effect on RA by inhibition of angiogenesis through down-regulation of angiogenesis related factors, HIF-1α and VEGF.
Introduction
Angiogenesis is an essential component in the formation and maintenance of infl ammatory synovial tissues in rheumatoid arthritis (RA) [1] as it allows these tissues to cope with the increased demand for oxygen and nutrients [2] . Previous studies demonstrated that the inhibition of angiogenesis ameliorated synovial infl ammation in animal models of arthritis [3] , suggesting that blockade of angiogenesis offered a promising therapeutic strategy for RA. However, the patho-mechanisms that control the development of synovial angiogenesis in RA are not fully understood.
Several growth factors, including fi broblast growth factors (FGFs), vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor (PD-ECGF), as well as soluble forms of several adhesion molecules are able to stimulate angiogenesis directly by interacting with endothelial cell receptors [4] . VEGF is of particular importance in the process of angiogenesis as it promotes endothelial cell migration and increases vascular permeability [5] . It is known that RA synoviocytes secrete VEGF, and synovial fl uids in RA patients contain abnormally high levels of VEGF [6, 7] . Accordingly, the VEGF receptors fl t-1 and fl k-1 are strongly expressed in endothelial cells of the RA synovium [4] . In clinical studies, administration of anti-TNFα antibody reduced serum levels of VEGF by up to 40 % in patients with RA; however, circulating VEGF levels remained signifi cantly higher than in healthy individuals [2] . Therefore, anti-angiogenic agents, including antibodies to VEGF and VEGF receptor antagonists, are currently being tested for their therapeutic use in RA [8] [9] [10] [11] [12] .
There are many angiogenic and angiostatic factors that regulate VEGF expression [5] . In all cell types studied to date, two transcription factors, hypoxia-inducible factor-1 (HIF-1) and HIF-2, which are induced to similar levels under hypoxic conditions, were shown to stimulate the VEGF gene promoter. While the HIF-1α subunit is rapidly degraded under normoxic conditions, under hypoxic conditions, it is stabilized and translocates to the nucleus, where it transactivates a number of genes with hypoxia-responsive elements in their promoters [13] . The HIF-2α subunit is highly expressed by vascular endothelial cells and activates the transcription of endothelial-cell-specifi c receptor tyrosine kinase and the VEGF receptor fl k-1. A previous study demonstrated signifi cant cytoplasmic and nuclear overexpression of HIF-1α and HIF-2α in the synovial lining and stromal cells in RA and in osteoarthritis synovial tissue [14] . More recently, Makino et al. reported that CD3-positive T cells which had accumulated in infl ammatory tissue expressed HIF-1α [15] . The authors postulated that hypoxia plays an important role in the survival of activated T cells via the HIF-1α-adrenomedullin cascade. These fi ndings suggest that HIF-1α is closely involved in synovial pathology and can thus serve as a therapeutic target for RA.
It has been shown that histone modifi cation through reversible acetylation is a crucial event in gene expression [16] . Histone acetylation is controlled by two enzymes, histone acetyltranferase (HAT) and histone deacetylase (HDAC) [17, 18] . Increasing evidence indicates that the antitumor activity of HDAC inhibitors is exerted through multiple mechanisms, such as apoptosis, cell cycle arrest, and differentiation, via the modulation of gene expression [19] [20] [21] [22] [23] [24] . Recent reports demonstrated that specifi c HDAC inhibitors, including trichostatin A (TSA) and depsipeptide (FK228), inhibit angiogenesis by altering HIF-1 expression and VEGF signaling [25] [26] [27] . This fi nding raised the questions whether HDAC inhibitor prevents angiogenesis within the infl ammatory joint by repressing hypoxia-induced HIF-1 and VEGF expression by rheumatoid arthritis synovial fibroblasts (RASFs). To answer that question, we investigated the in vitro effects of FK228, a specifi c HDAC inhibitor, on the expression of HIF-1α and VEGF by RASFs under hypoxic conditions. In addition, the in vivo effects of FK228 on the expression of VEGF and the number of blood vessels in synovial tissue were studied in mice with collagen-antibody-induced arthritis (CAIA). The results demonstrated a potential for benefi cial role of HDAC inhibitors in blockage of angiogenesis via suppression of angiogenesis-related factors in RA synovial tissue.
Materials and methods

Reagents
Recombinant human IL-1β and TNFα were purchased from R&D Systems (Minneapolis, MN), stored at -80 °C, and diluted in culture medium immediately before use. Mouse monoclonal antibody against HIF-1α was purchased from Novus Biologicals, Inc. (Littleton, CO). Rabbit polyclonal antibody against VEGF (A-20) was purchased from Santa Cruz Biotechnology, Inc. (CA, USA). FK228 was provided by Fujisawa Pharmaceutical Co., Ltd. (Osaka, Japan). For the in vitro studies, FK228 was dissolved in DMSO and diluted with each of the experimental media before use. For the in vivo studies, FK228 was dissolved in and diluted with 10 % polyoxythylene (60)-hydrogenated castor oil in saline (HCO60 saline).
Isolation and culture of human RASFs
Following the written permission of the patients, fresh synovial tissues were obtained from fi ve RA patients during total joint replacement surgery. The tissues were minced and then immediately digested with collagenase (Wako, Osaka, Japan) and DNAase (Sigma-Aldrich) at 37 °C, as previously described [28] . Tissue debris was removed with a cell strainer, and the remaining cells were washed twice with Dulbecco's modifi ed Eagle's medium (DMEM, Sigma-Aldrich) supplemented with 10 % HEPES (Life Technologies, Tokyo, Japan), 100 IU penicillin/ml, and 100 mg streptomycin/ml (Life Technologies). The resultant single-cells were dispensed into the wells of a 24-well microtiter plate (Costar, Cambridge, MA) at a density of 2 × 10 6 cells/ml in 2 ml of DMEM supplemented with 10 % fetal bovine serum (FBS; Life Technologies, Rockville, MD), 100 IU penicillin/ml, and 100 mg streptomycin/ml. The plates were incubated at 37 °C in a humidifi ed atmosphere containing 5 % CO 2 . Synovial-tissue cell cultures were divided once weekly until the primary cultures had reached confl uence. After the third passage, morphologically homogeneous fi broblast-like cells were obtained.
Hypoxic conditions
A sealed chamber (ASTEC APM-30D, Fukuoka, Japan) was used to culture cell preparations in a low-oxygen-tension environment of 1 % O 2 , 5 % CO 2 , and 94 % N 2 .
Quantitative real-time PCR for the detection of HIF-1a and VEGF mRNA
Cells were seeded at a density of 1 × 10 6 /well in 6-well culture dishes, stimulated with recombinant human IL-1β (1 ng/ml) and recombinant human TNFα (10 ng/ml) for 1 h, and then incubated with or without various concentrations of FK228 under 1 % O 2 for up to 24 h. The morphology of the cells was examined under polarized light microscopy, after which total RNA was isolated from cultured cells using Isogen reagent (Nippon Genhe, Toyama, Japan). The purifi ed RNA was reverse-transcribed using Rever Tra Ace (Toyobo, Tokyo, Japan).
For real-time PCR, the primer sequences of HIF-1α and VEGF were as follows: for HIF-1α, 5 -ATC ATG CAG CTA CTA CAT CA-3 (forward) and 5 -CTT CAC AAT CAT AAC TGG TC-3 (reverse); for VEGF, 5 -TCT TCA AGC CAT CCT GTG T-3 (forward) and 5 -CTT TCT TTG GTC TGC ATT C-3 (reverse); for β-actin, 5 -TTC CTG GGC ATG GAG TCC T-3 (forward) and 5 -AGG AGG AGC AAT GAT CTT GAT C-3 (reverse). Real-time PCR reactions were carried out using a LightCycler FastStart DNA Master SYBR green I kit (Roche Molecular Biochemicals, Mannheim, Germany) as recommended by the manufacturer. Gene expression was quantifi ed by dividing the level of HIF-1α and VEGF mRNA expression by the level of β-actin mRNA expression.
Analysis of HIF-1a and VEGF protein expression
Cells were seeded at a density of 2 × 10 5 cells/well in 6-well culture dishes, stimulated with TNFα and IL-1β as described above, and then incubated with FK228 (5 nM) under hypoxia for up to 24 h (0, 12, and 24 h). For analysis of HIF-1α, the cells were washed twice with PBS, scraped, and lysed, after which proteins were extracted in a buffer of icecold 1 % Triton X-100 in PBS supplemented with 1 mM PMSF, 2 mM N-ethylmaleimide, 5 mM iodoacetamide, and 1 mM EDTA. The resulting extract was incubated on ice for 5 min and centrifuged at 15,000 g for 10 min at 4 °C. The concentrations of proteins in the supernatant were measured and equalized using a Bio-Rad protein assay kit. Forty µg of protein per lane were run on 8 % SDS-PAGE gels and then transferred onto polyvinylidene difl uoride membranes (Immobilon, Millipore, Bedford, MA). Membranes were blocked with 1 % bovine serum albumin (BSA) in PBS, incubated with primary antibody diluted in blocking so-lution, washed with 0.05 % Triton X-100 in PBS, and then incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody diluted in blocking solution. Immuno-positive bands were detected using an enhanced chemiluminescence system (ECL, Amersham Phamacia Biotech). To confi rm that the amounts of protein were equal, β-actin was run as an internal control.
Culture supernatants of RASFs were collected at each time point (0, 12, and 24 h) after FK228 (5 nM) treatment and kept frozen at -80 °C until analyzed. VEGF protein secreted into the culture media by RASFs was quantifi ed using a human VEGF ELISA kit (R&D systems, Inc. Minneapolis, MN) according to the manufacturer's instructions. The values obtained from the experiments were adjusted to the total protein amounts in the culture media.
Induction of CAIA in mice
DBA/1 mice (Charles River Japan, Inc., Yokohama, Japan) were used to evaluate the in vivo effects of FK228 on VEGF expression in synovial tissue. All of the mice (n = 15) in the current study were 6-to 7-weeksold. They were fed a standard commercial diet and tap water ad libitum at the Laboratory Animal Center for Biochemical Research, Okayama University Graduate School of Medicine and Dentistry, under standard diurnal conditions. Arthritis was induced by an arthritogenic cocktail of four monoclonal antibodies (mAbs) to type II collagen (Chondrex Inc, Redmond, WA) combined with LPS simulation according to the method of Terato et al. [29, 30] . DBA/1 mice were injected intravenously with 2 mg of mAbs on day 0 and day 1 (total 4 mg) followed by intraperitoneal injection of 50 µg LPS on day 2. After the onset of clinically distinct arthritis, FK228 was intravenously administrated once on day 4 at 2 mg/ kg (n = 5). Control mice (n = 10) were injected with 10 % HCO60 saline alone on the same day (day 4).
Clinical evaluation of arthritis
The mice were monitored for the development of arthritis every day after the fi rst round of mAb injection. Arthritis was scored using a range of 0-4 points, according to the criteria of Terato et al. [29] . Each limb was graded individually, so that the maximum cumulative clinical arthritic score per mouse was 16 points.
Histological analysis of hind paws
The mice were euthanized by systemic perfusion with 4 % paraformaldehyde under general anesthesia. Both hind limbs of CAIA mice before treatment (n = 5), CAIA mice without treatment (n = 5), and CAIA mice with FK228 treatment (n = 5) were dissected on day 4, 6, and 6, respectively, and fi xed in the same solution for 24 h. The samples were decalcifi ed by incubation in 0.3 M EDTA (pH 7.5) for 7-10 days, divided into two blocks in the sagittal plane, dehydrated in a graded series of ethanol, and embedded in paraffi n. Hematoxylin and eosin staining, and Victoria-blue staining for elastic fi bers of the blood vessels were performed on standard sagittal sections of 4.5 µm. The histology of the synovial infl ammation as well as of the bone and cartilage damage was examined independently by two of the authors (KN and YN) . The sections were blinded and graded according to the system described by Sancho et al. [31] : 0, no infl ammation; 1, slight thickening of the synovial cell layer, and/or some infl ammatory cells in the sublining; 2, thickening of the synovial lining, infi ltration of the sublining, and localized cartilage erosions; and 3, infi ltration of the synovial space, pannus formation, cartilage destruction, and bone erosion. The number of blood vessels stained by Victoria-blue within the fi eld of 1 mm × 1 mm were counted in section of the tarsal joints of the hind limbs of normal mice without arthritis (n = 4), CAIA mice without treatment (n = 5) and CAIA mice with FK228 treatment (n = 5).
VEGF immunohistochemistry
The immunohistochemistry of VEGF was carried out as previously described [30] , with the same series of paraffi n sections used for the histological study. Endogenous peroxidase in the samples was blocked with 0.3 % H 2 O 2 , Antigen was unmasked by treating the sections with 1 mg of hyaluronidase (Streptomyces hyalurolyticus) (Seikagaku Co., Tokyo, Japan) per ml for 1 h at room temperature. After non-specifi c binding had been blocked with 5 % horse serum, the slides were incubated with polyclonal anti-VEGF antibody at 1: 100 overnight at 4 °C, and then with 7.5 µg biotinylated goat anti-rabbit IgG (Vector Laboratories Inc, CA) per ml for 30 min at room temperature. Histone Simple Stain MAX-PO (M) (Nichirei, Tokyo, Japan) and Simple Stain DAB solution (Nichirei) were used to visualize antibody binding. The sections were counterstained with hematoxylin. Negative control tissues were prepared in the same manner as described above, except for the omission of primary antibodies and the substitution of an isotype-matched but irrelevant antibody. The slides were blinded and scored by three independent observers (KN, YN, and HM) for VEGF staining using a 4-point scale: 0 = no staining, 1 = localized staining, 2 = widespread, but not total staining, and 3 = widespread, total staining of the synovial tissue. An average of the three observers' scores was determined, and the mean scores were statistically compared.
Statistical analysis
All RASF experiments were repeated at least three times and yielded similar results. Data were expressed as means ±SD. Statistical analysis was done using a one-way analysis of variance followed by either Fisher's least signifi cant difference test or the Mann-Whitney U test, using Statview-J 5.0 software (SAS Institute, Cary, NC); p < 0.05 was considered statistically signifi cant.
Results
FK228 inhibits the hypoxia-induced expression of HIF-1a and VEGF mRNA
The effects of FK228 on HIF-1α and VEGF mRNA expression in hypoxia-exposed RASFs were examined by quantitative real-time PCR. Neither hypoxia, FK228, nor a combination of both had an effect on cell morphology or cell survival during the 24-h experimental period (data not shown). FK228 down-regulated HIF-1α and VEGF mRNA expression under hypoxia in a dose-dependent manner (Fig.  1) . Statistical analysis showed that 5 nM of FK228 was suffi cient to inhibit the expression of HIF-1α and VEGF mRNA in RASFs. Under hypoxic conditions, HIF-1α expression was signifi cantly up-regulated at 6 h (p < 0.05), and VEGF expression at 12 h (p < 0.005). Stimulation of the cells with IL-1β (1 ng/ml) and TNF-α (10 ng/ml) further enhanced HIF-1α expression at 12 and 24 h, and VEGF expression at 12 h (p < 0.001). Cytokine stimulation under hypoxia enhanced HIF-1α mRNA expression in a time-dependent manner; VEGF mRNA expression increased up to 12 h but decreased by 24 h. FK228 (5 nM) signifi cantly down-regulated HIF-1α mRNA expression at 12 and 24 h ( Fig. 2A) , and VEGF mRNA expression at 12 and 24 h (Fig.  2B) (p < 0.001) . The experiments for each condition were done at least three times and generated similar data. To study whether the down-regulation of HIF-1α and VEGF mRNA induced by FK228 was related to HDAC inhibition, the effect of trichostatin A (TSA), a classic HDAC inhibitor, was Vol. 57, 2008 Inhibition of VEGF expression by HDAC inhibitor 7 examined. TSA also down-regulated the cytokine-induced expression of HIF-1α and VEGF mRNA under hypoxia (data not shown).
Effect of FK228 on HIF-1a and VEGF protein expression
The effect of FK228 (5 nM) on HIF-1α protein expression in RASFs was determined by Western blot analysis. The levels of HIF-1α protein increased under hypoxia in a time-dependent manner, whereas after incubation with FK228 (5 nM) the levels had decreased by 12 and 24 h (Fig. 3) . The effect of FK228 on the secretion of VEGF protein into the culture medium under hypoxia was also studied. VEGF secretion increased in a time-dependent manner under hypoxia (control) and was markedly up-regulated at 24 h following stimulation with IL-1β and TNFα. FK228 (5 nM) treatment signifi cantly decreased VEGF secretion in the culture medium to a level below that of the control ( Table 1) .
Suppression of VEGF expression and inhibition of angiogenesis by FK228 in the synovial tissue of CAIA mice
By day 4, clinically apparent arthritis, with marked swelling or redness of the limb joints, had developed in all mice. We previously reported that the symptoms of clinical arthritis in mice treated with FK228 were barely apparent on day 10 and continued to diminish until the end of the observation period on day 15 [28] . Therefore, synovial tissue samples collected at day 4 and 6 were used for histological and immunohistochemical analyses of VEGF. The mean clinical scores of control and FK228-treated CAIA mice on day 6 were 12.6 ± 1.3 points, and 7.8 ± 1.3 points, respectively. There was a signifi cant difference between the two groups (p < 0.001). Histologically, the hind-paw joint of control mice showed marked synovial proliferation and infi ltration by infl ammatory cells (Fig. 4A: a, b) . The joint-infl ammation score of control CAIA mice on day 4 and 6 were 0.9 ± 0.3, and 2.5 ± 0.5, respectively. In contrast, infl ammation was less severe in the synovial tissue of FK228-treated mice. The joint infl ammation score of the treated animals was 1.0 ± 0.7, which was signifi cantly lower than that of control mice (p < 0.001; Fig. 4B ). Intense staining for VEGF was noted in the synovial lining cells and in fi broblasts within the synovial tissue of control, non-treated mice. However, after treatment with FK228, VEGF expression signifi cantly diminished (Fig. 4A:  c, d) . The VEGF staining scores of control CAIA mice on day 4, control CAIA mice on day 6, and FK228-treated mice on day 6 were 1.1 ± 0.8, 2.5 ± 0.7 and 1.1 ± 1.1, respectively. The score of FK228-treated mice was signifi cantly lower than that of control mice (p < 0.005; Fig. 4C ).
Victoria-blue staining successfully labeled the elastic fi bers of blood vessels in the synovial tissue. The number of blood vessels within the fi eld of normal mice without arthri-vestigated the effects of FK228 on HIF-1α and VEGF expression in RASFs. Our results showed that, in response to hypoxia and stimulation with pro-infl ammatory cytokines, FK228 inhibited both the expression of HIF-1α and the induction of VEGF in RASFs at the mRNA and protein levels. The present study further demonstrated that intravenous administration of FK228 (2.5 mg/kg) effectively ameliorated joint infl ammation and suppressed VEGF expression in the synovial tissue of CAIA mice on day 6. Semi-quantitative analysis on the number of blood vessels in the synovial tissue tis, control CAIA mice on day 6, and FK228-treated mice on day 6 were 9.8 ± 2.2, 19.0 ± 3.4, and 12.2 ± 1.3, respectively. The number of blood vessels of FK228-treated mice was signifi cantly lower than that of control mice (p < 0.001; Fig. 5 ).
Discussion
We recently demonstrated that FK228, a specifi c inhibitor of HDAC, prevents the in vitro proliferation of RASFs and ameliorates the pathological changes of autoantibody-mediated arthritis in mice. Furthermore, we also showed that the effects of FK228 are controlled, at least in part, by the regulation of p16 INK4a and p21 Cip1/WAF1 gene expression [28] . The results strongly suggested that modulation of the transcriptional activity of specifi c promoters in response to the local release or perturbation of chromatin structure, by treatment with HDAC inhibitor, could effectively prevent the synovial proliferation and joint destruction seen in human RA. Nonetheless, the inhibitory effects on cell cycle regulation and cell proliferation were not suffi cient to explain the strong anti-infl ammatory effects of HDAC inhibitor that are exerted in vivo. Interestingly, several recent studies indicated that the inhibitory property of FK228 on hypoxia-induced angiogenesis occurred via suppression of both HIF-1α activity and VEGF mRNA expression [26, 27, 32] . As VEGF plays a central role in the angiogenic process in RA, we in- Vol. 57, 2008 Inhibition of VEGF expression by HDAC inhibitor 9
stained by Victoria-blue staining demonstrated the blockage of angiogenesis by FK228. These fi ndings suggest that the modifi cation of chromatin structure by HDAC inhibitors plays a benefi cial role in the control of synovial angiogenesis via regulation of hypoxia-regulated genes. The mechanism of the inhibitory effect on HIF-1α and VEGF expression by HDAC inhibitors is not fully understood. In the current study, the effect of HDAC inhibition by FK228 on HIF-1α expression was not apparent until 12 h. In HepG2 human hepatoblastoma cells, hypoxia-induced HDAC activity responded in a time-dependent manner, reaching a maximum at 16 hours [25] . The overexpression of wild-type HDAC1 in HepG2 cells resulted in signifi cant up-regulations of HIF-1α and VEGF mRNA [25] . These results suggest that the effect of FK228 on HIF-1α and VEGF mRNA might be partly exhibited by the direct inhibition of hypoxia-induced HDAC activity in RASF.
It is not still clear whether histone acetylation by HDAC inhibitors selectively modulates the expression of these genes under hypoxic conditions [32] . Lee et al. demonstrated that FK228 inhibited the hypoxia-induced expression and DNAbinding activity of HIF-1α in Lewis lung carcinoma cells. The direct effect of FK228 on HIF-1 activity was suggested to prohibit VEGF induction in response to hypoxia, thereby inhibiting tumor angiogenesis [32] . Sasakawa et al. reported histone acetylation of VEGF promoter regions and suppression of VEGF gene expression by FK228 in PC-3 prostate cancer cells. The authors speculated that the patterns of histone acetylation of VEGF differed from those involved in the up-regulation of gene expression. It was also suggested that the alterations in chromatin structure induced by FK228-mediated histone acetylation result in the failure of transcription-factor binding to VEGF gene promoters [27] . In RA joints, RASFs spontaneously release proinfl ammatory cytokines, such as IL-1, IL-6, IL-8, TGFβ, TNFα, all of which are potent inducers of angiogenesis in vivo [8, 9] . A variety of cytokines, including IL-1β and TNFα, are known to stabilize and activate HIF-1α [33, 34] . Stimulation of cultured RASFs by IL-1β increased HIF-1α mRNA levels as well as the binding of the heterodimer HIF-1 to the HIF consensus sequence [33] . IL-1β and TNF α stimulated HIF-1 binding to DNA in human hepatoma cells [34] . In the current study, the up-regulation of HIF-1α mRNA expression seen after 6 h stimulation might be mainly induced by exogenous IL-1β and TNFα without requiring de novo protein synthesis, because hypoxic regulation of HIF-1α occurs at the post-translational level by protein stabilization [33] . Among the HIF-1-inducible genes, only VEGF has been shown to be induced by IL-1β and TNF-α in RASFs [1, 33] . The fact that the effect of IL-1 on HIF-1 DNA-binding activity was not fully apparent until 6 hours stimulation in human synovial fi broblasts [33] might reasonably explain the relatively delayed up-regulation of cytokininduced VEGF mRNA expression to HIF-1 expression at 12 h seen in the current study. Furthermore, we demonstrated that FK228 inhibited the expression of IL-1β and TNF-α in the synovium of CAIA mice in a previous study [28] . Thus, it is possible that down-regulation of VEGF expression in vivo at 12 h might be induced by down-regulation of not only HIF-1α expression, but by suppression of endogenous IL-1β and TNF-α expression following FK228 treatment.
Another explanation for the down-regulation of VEGF gene expression by HDAC inhibition may be that HDAC inhibitors inactivate transcriptional factors other than HIF-1 by modifying the activities of cell cycle regulators. HDAC inhibitors are known to exert anti-arthritic properties by upregulation of p21
Cip1/WAF1 , a cyclin-dependent kinase (CDK) inhibitor, via acetylation of promoter regions of the gene [28, 35] . Recent report demonstrated that adenoviral p21 Cip1/WAF1 gene transfer into RASF resulted in the inhibition of infl ammatory gene expression by reducing the activity of c-Jun NH 2 -terminal kinase (JNK), which phosphorylates the c-Jun component of AP-1 transcriptional factor [36, 37] , or by inactivation of the transcription factor NF-κB [34] . The entire complex of AP-1 and HIF-1 contributes to the activation and expression of VEGF under hypoxic conditions. In addition, NF-κB is strongly activated by reoxygenation and is involved in the up-regulation of many infl ammatory genes, including VEGF [38] . Taken together, these fi ndings suggest that HDAC-inhibitor-induced up-regulation of p21 Cip1/WAF1 contributes to the inhibition of VEGF expression via inactivation of NF-κB and/or AP-1 in hypoxic RASFs.
In conclusion, we have demonstrated that FK228 downregulates the expression of hypoxia-induced HIF-1α and VEGF in RASF. Similarly, VEGF expression and number of blood vessels in synovial tissues decreased in the joints of CAIA mice treated by systemic administration of FK228. Further studies aimed at exploring the precise, HDAC-specifi c mechanisms underlying the regulation of oxygen-dependent gene expression and hypoxia-induced angiogenesis in RA are needed.
